In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:CMV treatment goals CMV treatment and monitoring recommendationsRole of secondary prophylaxisUse of CMV cell–mediated immunity (CMI) monitoring for CMV relapse riskUse of CMV CMI for secondary prophylaxis Proposed use of CMV CMI monitoring for secondary prophylaxisIncidence and outcomes with antiviral resistance Risk factors for CMV resistanceWhen to suspect antiviral resistance Testing for antiviral resistance using genotypic assaysOutcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virusTreatment recommendations for resistant/refractory CMVEfficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE studyTreatment algorithm for resistant/refractory CMV Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV Faculty:Raymund Razonable, MDProfessor of MedicineProgram Director, Infectious Diseases FellowshipVice Chair, Division of Infectious DiseasesMayo ClinicRochester, Minnesota Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related